Medivation (MDVN) Tops Q2 EPS by 13c

Medivation (NASDAQ: MDVN) reported Q2 EPS of $0.58, $0.13 better than the analyst estimate of $0.45. Revenue for the quarter came in at $175.7 million versus the consensus estimate of $159.42 million.

"XTANDI's performance, in both the U.S. and outside the U.S., demonstrates continued traction toward becoming a foundation of therapy for the treatment of metastatic castration-resistant prostate cancer," said David Hung, M.D., president and chief executive officer of Medivation. "Medivation will continue to pursue innovative programs that have the potential to make a meaningful impact in the quality of life of patients with serious disease."

For earnings history and earnings-related data on Medivation (MDVN) click here.

You May Also Be Interested In

• Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
• Equifax (EFX) shares tumble on weak Q1 revenue, guidance miss
• Endexx Corporation (EDXC) Reports Q1 Loss of $0.01